|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The present study is the first to indicate that the polymorphism of PTH/PTHrP receptor gene is closely related to the extent of bone mass reduction in pHPT and that this polymorphism would be one of the genetic factors responsible for the severity of the pathological state of pHPT.
|
11014383 |
2000 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Primary hyperparathyroidism (HPT), most commonly due to parathyroid adenoma, is a disorder characterized by excessive secretion of PTH.
|
10704427 |
2000 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This study was designed to evaluate the results of a series of patients with PHPT who underwent minimally invasive radioguided parathyroidectomy (MIRP) using very low dose (1 mCi) of TC-99m sestamibi (MIBI) without application of intraoperative parathyroid hormone (PTH) assay or frozen section analysis.
|
28192245 |
2017 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Cure rate was 88% in the normal PTH group, compared to 96% in classic PHPT (p = 0.02).
|
29134314 |
2018 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, combination Cl/PO4 with ALP might be a low-cost, simple, available predictive marker of PHPT in Chinese individuals, particularly Chinese remote region where the method used to measure PTH cannot be done.
|
28687737 |
2017 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Primary hyperparathyroidism (PHP; serum calcium 2.75 mmol/L, PTH 226 pg/ml) had been the first clinical manifestation of MEN-2A in a female patient (aged 55 years) with a mutation (Y791F, TAT-->TTT) in exon 13 of the RET proto-oncogene.
|
16356097 |
2005 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recently, normocalcemic (NC) and normohormonal (NH) variants of primary hyperparathyroidism (pHPT) have been described, with distinct biochemical profiles from the typical high serum calcium and parathyroid hormone (PTH) levels.
|
31511943 |
2020 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In primary hyperparathyroidism (PHPT), hypersecretion of PTH leads to enhanced bone resorption and formation with increased risk of fracture.
|
15207766 |
2004 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
LNP patients had a milder form of pHPT (Ca<sup>2+</sup> 2.63 vs. 2.68 P < 0.05) with a smaller PTH and Ca<sup>2+</sup> drop post-operatively.
|
31773224 |
2020 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In hypertensive PHPT, 24 hours systolic blood pressure was associated only with parathyroid hormone (PTH) levels (beta = 0.36, p = 0.04). aPWV was associated with retinal diameter (beta = -0.69, p = 0.003), but not with PTH.
|
30410012 |
2018 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Primary hyperparathyroidism (HPT) is one of the most common endocrine disorders, defined by hypersecretion of parathormone.
|
24595969 |
2015 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Rapid intraoperative parathyroid hormone (ioPTH) monitoring measures postoperative reduction of parathyroid hormone (PTH) to predict surgical outcome in patients with primary hyperparathyroidism, and therefore contributes to the change of parathyroidectomy to a minimally invasive procedure.
|
29357735 |
2018 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In recent years, patients with primary hyperparathyroidism (PHPT) are being diagnosed earlier, with milder elevations in parathyroid hormone (PTH) and serum calcium.
|
27302092 |
2018 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Significant lower BMD in the distal radius with similar PTH levels was found in the minor allele homozygotes (GG) compared to heterozygotes and major allele homozygotes in both OPG rs3102735 (163 A/G) and OPG rs3134070 (245 T/G) SNPs in those with PHPT compared to control subjects.
|
22185226 |
2011 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Patients (Paris: 65 with FHH, 85 with PHPT; Aarhus: 38 with FHH, 55 with PHPT) were adults with hypercalcemia and PTH concentration within normal range.
|
29727008 |
2018 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This is a retrospective cohort study of 2,654 patients with primary hyperparathyroidism who underwent parathyroidectomy with intraoperative parathyroid hormone monitoring at a single institution from 1999 to 2014.
|
30975497 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Primary hyperparathyroidism is excluded by the immunoradiometric assay for parathyroid hormone, which is suppressed.
|
8060769 |
1994 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
We suggest that sustained stimulation of PTH receptors present in brain, muscle, and hematopoietic cells have to be considered as one independent, important cause of molecular disease in PHPT leading to profound alterations in gene expression that may help explain symptoms like muscle fatigue, cardiovascular pathology, and precipitation of psychiatric illness.
|
17227961 |
2007 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Only in pHPT was a negative correlation of borderline significance between serum parathormone (PTH) and number of aberrated chromosomes noticed (tau=-0.258, p=0.07).
|
17514620 |
2007 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Primary hyperparathyroidism (PHPT) is characterised by increased production of parathyroid hormone (PTH) resulting in elevated serum calcium levels.
|
21698093 |
2011 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
The set point for parathyroid hormone (PTH) secretion is increased in patients with primary hyperparathyroidism, possibly because of receptor defect(s).
|
9854589 |
1998 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Primary hyperparathyroidism (pHPT) is a common endocrine disease characterized by excessive secretion of parathyroid hormone and an increased level of serum calcium.
|
27071708 |
2016 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Primary hyperparathyroidism is commonly caused by excess production of parathyroid hormone from sporadic parathyroid adenomas.
|
29982334 |
2018 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
In this short pilot investigation, 1 week of maximally titrated ACEi did not impact PTH in participants without P-HPT, but resulted in a modest and marginally significant reduction of PTH but not calcium, among participants with P-HPT.
|
28808443 |
2017 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Thus, we studied 29 patients with FBH from 11 families, 29 age- and sex-matched controls, and 42 patients with primary hyperparathyroidism (1 degree HPT), measuring PTH with a highly sensitive two-site immunochemiluminometric assay and the hypercalcemic tumor factor PTH-related peptide (PTHrP) with an extraction/concentration RIA.
|
1997510 |
1991 |